FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Immutep approaches Lag3 crunch time
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
Yervoy delivers a surprise in liver cancer
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
Merck matches Kelun’s saci-tirumo efforts
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.
AACR 2024 preview – clinical highlights and lowlights
The 2024 AACR abstract title drop features several noteworthy clinical studies.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
